Loading...

News

News2019-01-16T06:35:03+00:00
CompanyCategoryTitleDate Downloademerald_news_company_hfilteremerald_news_category_hfilter
CompanyCategoryTitleDate Downloademerald_news_company_hfilteremerald_news_category_hfilter
Emerald Health Pharmaceuticals to Present at the Rodman & Renshaw 20th Annual Global Investment ConferenceAugust 28, 2018emerald-health-pharmaceuticalspress-release
NEMUS Bioscience to Present at the Rodman & Renshaw 20th Annual Global Investment ConferenceAugust 28, 2018nemus-biosciencepress-release
Emerald Health Therapeutics Signs Term Sheet to Access Large- Scale Extraction, Softgel Production, and New Product Development Capabilities Through Strategic Alliance with Factors Group of Nutritional CompaniesAugust 27, 2018emerald-health-therapeuticspress-release
Emerald Health Therapeutics Engages Acorn Management Partners for Investor RelationsAugust 24, 2018emerald-health-therapeuticspress-release
Emerald Health Therapeutics Announces Amendment to Pure Sunfarms’ Cultivation License, Substantially Expanding Cannabis Production Area to Approximately 420,000 Square FeetAugust 23, 2018emerald-health-therapeuticspress-release
Emerald Health Pharmaceuticals Announces Scientific Innovation Award Received at International Cannabis Research Society ConferenceAugust 21, 2018emerald-health-pharmaceuticalspress-release
Emerald Health Therapeutics Announces Appointment of Pure Sunfarms President and CEOAugust 21, 2018emerald-health-therapeuticspress-release
UPDATE: Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid- Based Active Pharmaceutical Ingredient for GlaucomaAugust 1, 2018nemus-biosciencepress-release
CompanyCategoryTitleDate Downloademerald_news_company_hfilteremerald_news_category_hfilter
CompanyCategoryTitleDate Downloademerald_news_company_hfilteremerald_news_category_hfilter